## Ludwig Kiesel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5864190/publications.pdf Version: 2024-02-01



LUDWIC KIESEI

#	Article	IF	CITATIONS
1	World Endometriosis Society consensus on the classification of endometriosis. Human Reproduction, 2017, 32, 315-324.	0.4	424
2	HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 1715-1720.	3.2	249
3	Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Research and Treatment, 2005, 90, 15-23.	1.1	209
4	miR-145-dependent targeting of Junctional Adhesion Molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene, 2010, 29, 6569-6580.	2.6	197
5	Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis, 2009, 30, 397-407.	1.3	168
6	Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenetics and Genomics, 2005, 15, 451-456.	0.7	159
7	Targeting of syndecanâ€1 by microRNA miRâ€10b promotes breast cancer cell motility and invasiveness <i>via</i> a Rhoâ€CTPase―and Eâ€cadherinâ€dependent mechanism. International Journal of Cancer, 2012, 131 E884-96.	,2.3	145
8	Male smokers have a decreased success rate for in vitro fertilization and intracytoplasmic sperm injection. Fertility and Sterility, 2003, 79, 1550-1554.	0.5	134
9	Characterization of endometrial mesenchymal stem-like cells obtained by endometrial biopsy during routine diagnostics. Fertility and Sterility, 2011, 95, 423-426.	0.5	112
10	Defective glycosylation of decorin and biglycan, altered collagen structure, and abnormal phenotype of the skin fibroblasts of an Ehlers–Danlos syndrome patient carrying the novel Arg270Cys substitution in galactosyltransferase I (β4GalT-7). Journal of Molecular Medicine, 2006, 84, 583-594.	1.7	104
11	Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. British Journal of Cancer, 2006, 95, 347-354.	2.9	104
12	Syndecan-1 (CD138) Modulates Triple-Negative Breast Cancer Stem Cell Properties via Regulation of LRP-6 and IL-6-Mediated STAT3 Signaling. PLoS ONE, 2013, 8, e85737.	1.1	104
13	Endothelin-1-, Endothelin-A-, and Endothelin-B-Receptor Expression Is Correlated with Vascular Endothelial Growth Factor Expression and Angiogenesis in Breast Cancer. Clinical Cancer Research, 2004, 10, 2393-2400.	3.2	103
14	Syndecanâ€1 modulates βâ€integrinâ€dependent and interleukinâ€6â€dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. FEBS Journal, 2013, 280, 2216-2227.	2.2	94
15	An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Research, 2007, 9, R8.	2.2	93
16	Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clinical Cancer Research, 2003, 9, 4125-31.	3.2	91
17	microRNA miR-142-3p Inhibits Breast Cancer Cell Invasiveness by Synchronous Targeting of WASL, Integrin Alpha V, and Additional Cytoskeletal Elements. PLoS ONE, 2015, 10, e0143993.	1.1	89
18	Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. The Cochrane Library, 2018, 2018, CD010287.	1.5	88

#	Article	IF	CITATIONS
19	MicroRNA miR-145 inhibits proliferation, invasiveness, and stem cell phenotype of an inÂvitro endometriosis model by targeting multiple cytoskeletal elements and pluripotency factors. Fertility and Sterility, 2013, 99, 1346-1355.e5.	0.5	85
20	miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro. Tumor Biology, 2018, 40, 101042831879188.	0.8	85
21	The adult stem cell marker Musashiâ€1 modulates endometrial carcinoma cell cycle progression and apoptosis <i>via</i> Notchâ€1 and p21 <sup>WAF1/CIP1</sup> . International Journal of Cancer, 2011, 129, 2042-2049.	2.3	83
22	Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. Journal of Cancer Research and Clinical Oncology, 2003, 129, 375-382.	1.2	82
23	microRNA miR-200b affects proliferation, invasiveness and stemness of endometriotic cells by targeting ZEB1, ZEB2 and KLF4. Reproductive BioMedicine Online, 2016, 32, 434-445.	1.1	76
24	Mechanism of action of gonadotropin releasing hormone: Role of lipoxygenase products of arachidonic acid in luteinizing hormone release. The Journal of Steroid Biochemistry, 1985, 23, 711-717.	1.3	73
25	Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer, 2008, 8, 62.	1.1	73
26	Enoxaparin Improves the Course of Dextran Sodium Sulfate-Induced Colitis in Syndecan-1-Deficient Mice. American Journal of Pathology, 2010, 176, 146-157.	1.9	71
27	Phosphatidic acid and the calcium-dependent actions of gonadotropin-releasing hormone in pituitary gonadotrophs. Archives of Biochemistry and Biophysics, 1984, 231, 202-210.	1.4	70
28	Follicular Fluid High Density Lipoprotein-associated Sphingosine 1-Phosphate Is a Novel Mediator of Ovarian Angiogenesis. Journal of Biological Chemistry, 2006, 281, 5398-5405.	1.6	66
29	Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Research and Treatment, 1993, 25, 37-46.	1.1	62
30	Gonadotropin releasing hormone enhances polyphosphoinositide hydrolysis in rat pituitary cells. Biochemical and Biophysical Research Communications, 1986, 134, 861-867.	1.0	61
31	Increased microvessel density in adenomyosis uteri. Fertility and Sterility, 2001, 75, 131-135.	0.5	59
32	On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Research and Treatment, 2007, 106, 361-369.	1.1	59
33	<i>HS3ST2</i> modulates breast cancer cell invasiveness via MAP kinase―and Tcf4 (Tcf7l2)â€dependent regulation of protease and cadherin expression. International Journal of Cancer, 2014, 135, 2579-2592.	2.3	58
34	Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082, November 2017) – Recommendations and Statements for Girls and Women. Geburtshilfe Und Frauenheilkunde, 2018, 78, 567-584.	0.8	56
35	Role of the Heparan Sulfate Proteoglycan Syndecan-1 (CD138) in Delayed-Type Hypersensitivity. Journal of Immunology, 2009, 182, 4985-4993.	0.4	54
36	Preterm birth but not mode of delivery is associated with an increased risk of developing inflammatory bowel disease later in life. Inflammatory Bowel Diseases, 2007, 13, 1385-1390.	0.9	52

#	Article	IF	CITATIONS
37	Changes in heparan sulfate are associated with delayed wound repair, altered cell migration, adhesion and contractility in the galactosyltransferase I (ß4GalT-7) deficient form of Ehlers–Danlos syndrome. Human Molecular Genetics, 2008, 17, 996-1009.	1.4	52
38	Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas, 2020, 135, 82-88.	1.0	51
39	Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Research and Treatment, 2010, 121, 301-309.	1.1	50
40	Role of the RANK/RANKL pathway in breast cancer. Maturitas, 2016, 86, 10-16.	1.0	48
41	Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling. Molecular Cancer, 2014, 13, 174.	7.9	45
42	Aberrant expression of the pluripotency marker SOX-2 in endometriosis. Fertility and Sterility, 2011, 95, 338-341.	0.5	44
43	Metformin alters insulin signaling and viability of human granulosa cells. Fertility and Sterility, 2005, 84, 1173-1179.	0.5	41
44	Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Research, 2006, 26, 621-7.	0.5	41
45	Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion. Fertility and Sterility, 2013, 99, 871-881.e1.	0.5	39
46	The Mediterranean diet and menopausal health: An EMAS position statement. Maturitas, 2020, 139, 90-97.	1.0	39
47	Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. Maturitas, 2020, 131, 91-101.	1.0	37
48	Stimulation of luteinizing hormone release by melittin and phospholipase A2 in rat pituitary cells. Molecular and Cellular Endocrinology, 1987, 51, 1-6.	1.6	36
49	Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas, 2021, 148, 55-61.	1.0	35
50	Detection of peritoneal endometriotic lesions by autofluorescence laparoscopy. American Journal of Obstetrics and Gynecology, 2006, 195, 949-954.	0.7	34
51	Collagen I triggers directional migration, invasion and matrix remodeling of stroma cells in a 3D spheroid model of endometriosis. Scientific Reports, 2021, 11, 4115.	1.6	33
52	Stimulation of Luteinizing Hormone Release and Cyclic Nucleotide Production by Arachidonic Acid in Cultured Pituitary Gonadotrophs. Neuroendocrinology, 1987, 46, 1-9.	1.2	31
53	Effects of luteinising-hormone-releasing hormone on nervous-system tumours. Lancet, The, 1998, 352, 372-373.	6.3	31
54	Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) – Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1089-1109.	0.8	30

#	Article	IF	CITATIONS
55	Stimulation of gonadotropin release by arachidonic acid and its lipoxygenase metabolites in superfused pituitary cells. Life Sciences, 1987, 40, 847-851.	2.0	29
56	COX-2 overexpression in peritoneal lesions is correlated with nonmenstrual chronic pelvic pain. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 124, 216-221.	0.5	29
57	Epidermal growth factor stimulates luteinizing hormone and arachidonic acid release in rat pituitary cells. Molecular and Cellular Endocrinology, 1988, 57, 157-162.	1.6	28
58	Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes and Cancer, 2006, 45, 905-917.	1.5	28
59	Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement. Maturitas, 2021, 151, 55-62.	1.0	28
60	Management of urinary incontinence in postmenopausal women: An EMAS clinical guide. Maturitas, 2021, 143, 223-230.	1.0	27
61	Menstrual abnormalities and predisposition to pregnancy-related hypertensive disorders: a retrospective study. Gynecological Endocrinology, 2010, 26, 445-450.	0.7	26
62	Knockdown of Musashi RNA Binding Proteins Decreases Radioresistance but Enhances Cell Motility and Invasion in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 2169.	1.8	26
63	Inhibition of human placental progesterone synthesis and aromatase activity by synthetic steroidogenic inhibitors in vitro. Fertility and Sterility, 1983, 39, 829-835.	0.5	25
64	Endometriosis: A genetic disease. Drugs of Today, 2003, 39, 961.	2.4	25
65	Caveolin-1 expression in benign and malignant lesions of the breast. World Journal of Surgical Oncology, 2007, 5, 110.	0.8	24
66	Genomic Profiling in Triple-Negative Breast Cancer. Breast Care, 2013, 8, 408-413.	0.8	24
67	Effects of black cohosh on estrogen biosynthesis in normal breast tissue in vitro. Maturitas, 2007, 57, 382-391.	1.0	23
68	Advanced follicle development in xenografted prepubertal ovarian tissue: the common marmoset as a nonhuman primate model for ovarian tissue transplantation. Fertility and Sterility, 2011, 95, 1428-1434.	0.5	23
69	Serum estradiol and progesterone in the mid-luteal phase predict clinical pregnancy outcome in IVF/ICSI cycles. Gynecological Endocrinology, 2013, 29, 700-703.	0.7	23
70	Endocytosis of the dermatan sulfate proteoglycan decorin utilizes multiple pathways and is modulated by epidermal growth factor receptor signaling. Biochimie, 2007, 89, 637-657.	1.3	22
71	Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion. Breast Cancer Research and Treatment, 2008, 108, 175-182.	1.1	22
72	miR-142-3p is a novel regulator of cell viability and proinflammatory signalling in endometrial stroma cells. Reproductive BioMedicine Online, 2015, 30, 553-556.	1.1	22

#	Article	IF	CITATIONS
73	The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling. Gynecological Endocrinology, 2015, 31, 160-164.	0.7	22
74	Strain Elastography as a New Method for Assessing Pelvic Floor Biomechanics. Ultrasound in Medicine and Biology, 2017, 43, 868-872.	0.7	22
75	The endometrial stem cell markers notch-1 and numb are associated with endometriosis. Reproductive BioMedicine Online, 2018, 36, 294-301.	1.1	21
76	A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes) Tj ETQ	90000rgE	T  Overlock 1
77	Physiological Concept for a Blood Based CFTR Test. Cellular Physiology and Biochemistry, 2006, 17, 29-36.	1.1	20
78	ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. Breast Cancer Research and Treatment, 2010, 123, 345-357.	1.1	20
79	Breast cancer molecular subtypes – Modern therapeutic concepts for targeted therapy of a heterogeneous entity. Maturitas, 2012, 73, 288-294.	1.0	20
80	FSH prevents depletion of the resting follicle pool by promoting follicular number and morphology in fresh and cryopreserved primate ovarian tissues following xenografting. Reproductive Biology and Endocrinology, 2012, 10, 98.	1.4	20
81	The Heparan Sulfate Sulfotransferases HS2ST1 and HS3ST2 Are Novel Regulators of Breast Cancer Stem-Cell Properties. Frontiers in Cell and Developmental Biology, 2020, 8, 559554.	1.8	20
82	Endothelin-1, Endothelin-A- and Endothelin-B-receptor expression in preinvasive and invasive breast disease. Oncology Reports, 2004, 11, 791-6.	1.2	20
83	HS2ST1â€dependent signaling pathways determine breast cancer cell viability, matrix interactions, and invasive behavior. Cancer Science, 2020, 111, 2907-2922.	1.7	19
84	A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core) Tj ETQq0 0 0 rg	gBT/Overlo	ock 10 Tf 50 :
85	Targeting endothelin A receptor enhances antiâ€proliferative and antiâ€invasive effects of the HER2 antibody trastuzumab in HER2â€overexpressing breast cancer cells. International Journal of Cancer, 2010, 127, 696-706.	2.3	18
86	Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer. Breast Care, 2011, 6, 1-1.	0.8	18

87	Arachidonic acid and its lipoxygenase metabolites stimulate prolactin release in superfused pituitary cells. Human Reproduction, 1987, 2, 281-285.	0.4	17
88	Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes. Cancers, 2021, 13, 2318.	1.7	17
89	Knockdown of the prognostic cancer stem cell marker Musashi-1 decreases radio-resistance while enhancing apoptosis in hormone receptor-positive breast cancer cells via p21WAF1/CIP1. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3299-3312.	1.2	17
90	Regulation of human placental progesterone synthesis in vitro by naturally occurring steroids. The Journal of Steroid Biochemistry, 1985, 22, 657-664.	1.3	16

6

#	Article	IF	CITATIONS
91	Detection of Nonpigmented Endometriotic Lesions with 5-Aminolevulinic Acid-Induced Fluorescence. Journal of Minimally Invasive Gynecology, 2004, 11, 505-510.	1.4	16
92	Longâ€ŧerm efficacy of glycerineâ€processed amniotic membrane transplantation in patients with corneal ulcer. Acta Ophthalmologica, 2015, 93, e481-7.	0.6	16
93	Serum Concentration and Urinary Excretion of the Luteinizing Hormone-Releasing Hormone Agonist Buserelin in Patients with Endometriosis. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 1167-1173.	1.8	15
94	Perioperative complications in conventional and microsurgical abdominal myomectomy. Archives of Gynecology and Obstetrics, 2011, 284, 137-144.	0.8	15
95	γâ€&ecretase inhibition affects viability, apoptosis, and the stem cell phenotype of endometriotic cells. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 1565-1574.	1.3	15
96	Assessment of three-dimensional sonographic features of polycystic ovaries after laparoscopic ovarian electrocautery. Fertility and Sterility, 2007, 88, 894-899.	0.5	14
97	Evaluation of placental syndecanâ€l expression in early pregnancy as a predictive fetal factor for pregnancy outcome. Prenatal Diagnosis, 2012, 32, 131-137.	1.1	14
98	Prognostic significance of hedgehog signaling networkâ€related gene expression in breast cancer patients. Journal of Cellular Biochemistry, 2021, 122, 577-597.	1.2	14
99	Overexpression of Endothelin-A-receptor in breast cancer: regulation by estradiol and cobalt-chloride induced hypoxia. International Journal of Oncology, 2005, 26, 951-60.	1.4	14
100	Impact of Musashi-1 and Musashi-2 Double Knockdown on Notch Signaling and the Pathogenesis of Endometriosis. International Journal of Molecular Sciences, 2022, 23, 2851.	1.8	14
101	Imaging of fetal thymus in pregnant women with rheumatic diseases. Journal of Perinatal Medicine, 2014, 42, 635-639.	0.6	13
102	Syndecan-4 expression is upregulated in endometriosis and contributes to an invasive phenotype. Fertility and Sterility, 2016, 106, 378-385.	0.5	13
103	Correlation between SFRP1 expression and clinicopathological parameters in patients with triple-negative breast cancer. Future Oncology, 2019, 15, 1921-1938.	1.1	13
104	Analysis of hormonal changes during combined buserelin/HMG treatment*. Human Reproduction, 1990, 5, 675-681.	0.4	12
105	Exogenous action of 5-lipoxygenase by its metabolites on luteinizing hormone release in rat pituitary cells. Molecular and Cellular Endocrinology, 1990, 69, 33-39.	1.6	12
106	Role of syndecan-3 polymorphisms in obesity and female hyperandrogenism. Journal of Molecular Medicine, 2009, 87, 1241-1250.	1.7	12
107	Impact of testosterone on the expression of organic anion transporting polypeptides (OATP-1A2,) Tj ETQq1 1 0.7 376-384.	784314 rg 1.0	BT /Overloc 12
108	microRNAâ€140â€3p modulates invasiveness, motility, and extracellular matrix adhesion of breast cancer cells by targeting syndecanâ€4. Journal of Cellular Biochemistry, 2021, 122, 1491-1505.	1.2	12

#	Article	IF	CITATIONS
109	Studies on the subcellular mechanisms mediating the negative estradiol effect on GnRH-induced LH-release by rat pituitary cells in culture. European Journal of Endocrinology, 1989, 121, 350-360.	1.9	11
110	Differential effect of hormone therapy on E1S-sulfatase activity in non-malignant and cancerous breast cells inÂvitro. Breast Cancer Research and Treatment, 2008, 108, 363-374.	1.1	11
111	Top concentrations of dynorphin-like immunoreactivity in fractions of rat anterior pituitary cells enriched in gonadotrophs. Life Sciences, 1986, 38, 2363-2367.	2.0	10
112	mRNA-Expression of ERα, ERβ, and PR in Clonal Stem Cell Cultures Obtained from Human Endometrial Biopsies. Scientific World Journal, The, 2011, 11, 1762-1769.	0.8	10
113	Seminal plasma (SP) induces a rapid transforming growth factor beta 1 (TGFβ1)â€"independent up-regulation of epithelialâ€"mesenchymal transdifferentiation (EMT) and myofibroblastic metaplasia-markers in endometriotic (EM) and endometrial cells. Archives of Gynecology and Obstetrics. 2019. 299. 173-183.	0.8	10
114	Obesity Epidemic—The Underestimated Risk of Endometrial Cancer. Cancers, 2020, 12, 3860.	1.7	10
115	Resveratrol impairs cellular mechanisms associated with the pathogenesis of endometriosis. Reproductive BioMedicine Online, 2022, 44, 976-990.	1.1	10
116	Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART. Journal of Assisted Reproduction and Genetics, 2005, 22, 277-283.	1.2	9
117	MicroRNAs and the pathogenesis of endometriosis. Journal of Endometriosis, 2012, 4, 1-16.	1.0	9
118	Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) – Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 949-971.	0.8	9
119	The Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 Promotes Ovarian Cancer Pathogenesis. International Journal of Molecular Sciences, 2022, 23, 5793.	1.8	9
120	Expression of PRL-3 regulates proliferation and invasion of breast cancer cells in vitro. Archives of Gynecology and Obstetrics, 2017, 296, 1153-1160.	0.8	8
121	miR-142-3p Reduces the Size, Migration, and Contractility of Endometrial and Endometriotic Stromal Cells by Targeting Integrin- and Rho GTPase-Related Pathways That Regulate Cytoskeletal Function. Biomedicines, 2020, 8, 291.	1.4	8
122	Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level,) Tj ETQq0 Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities. Geburtshilfe Und Frauenbeilkunde, 2022, 82, 181-205.	0 0 rgBT /( 0.8	Overlock 10 T 8
123	Overexpression of Endothelin-A-receptor in breast cancer: Regulation by estradiol and cobalt-chloride induced hypoxia. International Journal of Oncology, 2005, 26, 951.	1.4	7
124	Fetal myocardial peak systolic strain before and after intrauterine red blood cell transfusion – a tissue Doppler imaging study. Journal of Perinatal Medicine, 2012, 40, 545-550.	0.6	7
125	Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. European Journal of Cancer, 2012, 48, 2066-2074.	1.3	7
126	The role of prostaglandins, cyclic nucleotides and tricarboxylic acids in the regulation of the human placental 20α-hydroxysteroid dehydrogenase in vitro. Steroids, 1982, 40, 99-108.	0.8	6

#	Article	IF	CITATIONS
127	Contraceptive progestins and gonadotropin secretion In vitro. The Journal of Steroid Biochemistry, 1987, 27, 995-1002.	1.3	6
128	Serum inhibin levels in gonadotrophin stimulated in-vitro fertilization/gamete intra-Fallopian transfer cycles. Human Reproduction, 1992, 7, 1195-1200.	0.4	6
129	Effect of testosterone on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro. Journal of Steroid Biochemistry and Molecular Biology, 2009, 117, 168-175.	1.2	6
130	Differential Impact of Membrane-Bound and Soluble Forms of the Prognostic Marker Syndecan-1 on the Invasiveness, Migration, Apoptosis, and Proliferation of Cervical Cancer Cells. Frontiers in Oncology, 2022, 12, 803899.	1.3	5
131	The heparan sulphate proteoglycan Syndecan†( <scp>CD138</scp> ) regulates tumour progression in a 3D model of ductal carcinoma in situ of the breast. IUBMB Life, 2022, 74, 955-968.	1.5	5
132	Inhibition of human placental progesterone synthesis by danazol in vitro. Fertility and Sterility, 1983, 40, 330-333.	0.5	4
133	Association of Inhibin B Serum Levels with Parameters of Follicular Response in a Randomized Controlled Trial Comparing GnRH Agonist Versus Antagonist Protocols for Ovarian Hyperstimulation. Journal of Assisted Reproduction and Genetics, 2004, 21, 249-255.	1.2	4
134	The hyaluronan-related genes HAS2, HYAL1-4, PH20 and HYALP1 are associated with prognosis, cell viability and spheroid formation capacity in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3399-3419.	1.2	4
135	The impact of testosterone, tibolone and black cohosh on purified mammary and placental 17β-hydroxysteroid dehydrogenase type 1. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 448-457.	2.5	3
136	Effects of black cohosh on estrogen biosynthesis in hippocampus of non-human primates ex vivo in vitro and in human neuroblastoma cells in vitro. Clinical Phytoscience, 2017, 2, .	0.8	3
137	Reverse engineering of triple-negative breast cancer cells for targeted treatment. Maturitas, 2018, 108, 24-30.	1.0	3
138	Abstract 5580: Wnt signaling as chemotherapy sensitivity marker of triple negative breast cancer (TNBC) Cancer Research, 2013, 73, 5580-5580.	0.4	3
139	Action and formation of inositol bisphosphate and inositol trisphosphate in rat anterior pituitary cells. European Journal of Endocrinology, 1990, 123, 459-463.	1.9	2
140	Effects of hormone therapy on estrogen synthesis from E1S in the mammary gland of postmenopausal women. Maturitas, 2008, 59, 163-173.	1.0	2
141	Spontaneous conception and live birth after gonadotoxic chemotherapy for an aggressive bilateral ovarian Burkitt's lymphoma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 158, 362-364.	0.5	2
142	Endobronchial mucosal metastases in breast cancer: a rare metastatic pattern. Lancet Oncology, The, 2002, 3, 702-703.	5.1	1
143	Abstract 3496: Improvement of response to chemotherapy in breast cancer cells by the use of the non-oncologic drug minocycline. , 2015, , .		1
144	News from the San Antonio Breast Cancer Symposium 2010. Breast Care, 2011, 6, 56-61.	0.8	0

#	Article	IF	CITATIONS
145	Bridging the Gap - an Update of Translational Research in Breast Cancer. Breast Care, 2013, 8, 397-398.	0.8	0
146	Molecular analysis of the angiogenic status in endometriotic lesions and eutopic endometrium. , 0, 2004, .		0
147	Abstract 3024: Elucidation of WNT signaling pathway players "sFRP-1―and "TCF7L2―as novel potential biomarkers of triple negative breast cancer. , 2012, , .		Ο
148	Abstract 1198: Conversion of triple negative breast cancer cells into HER2 positive cells - a novel therapeutic approach. , 2012, , .		0
149	Abstract LB-211: Targeting triple negative breast cancer by using non-oncologic drug targets , 2013, , .		0
150	Abstract 2634: Direct reprogramming of tumor cells: a basis for novel therapeutic approaches. , 2014, ,		0
151	Abstract 920: Secreted frizzled related protein 1 (SFRP1) as potential regulator of chemotherapy response for patients with triple negative breast cancer (TNBC). , 2014, , .		0
152	Abstract LB-101: The antiandrogen drug dutasteride sensitizes triple negative breast cancer cells to chemotherapy via HIF-1Î $\pm$ / VEGF-signaling. , 2014, , .		0
153	Endometriosis – how should we classify?. Gynecological Endocrinology, 2022, 38, 449-449.	0.7	0